Asosiy kontentga oʻtish
Maqola

TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

Na TangInstitute of ZoologyChen ChengSchool of Life Sciences, University of Science and Technology of China, Hefei, Anhui, ChinaXingying ZhangInstitute of ZoologyMiaomiao QiaoState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, ChinaNa LiState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, ChinaWei MuInstitute of ZoologyXiao-Fei WeiBeijing Cord Blood Bank, Beijing, ChinaWeidong HanDepartment of Molecular Biology and Immunology, Chinese People’s Liberation Army General Hospital, Beijing, ChinaHaoyi WangSchool of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China
2020en
ABI

Annotatsiya

In recent years, chimeric antigen receptor-modified T cell (CAR T cell) therapy has proven to be a promising approach against cancer. Nonetheless, this approach still faces multiple challenges in eliminating solid tumors, one of which being the immunosuppressive tumor microenvironment (TME). Here, we demonstrated that knocking out the endogenous TGF-β receptor II (TGFBR2) in CAR T cells with CRISPR/Cas9 technology could reduce the induced Treg conversion and prevent the exhaustion of CAR T ce lls. Meanwhile, TGFBR2-edited CAR T cells had better in vivo tumor elimination efficacy, both in cell line-derived xenograft and patient-derived xenograft solid tumor models, whether administered locally or systemically. In addition, the TGFBR2-edited CAR T cells could eliminate contralaterally reinoculated xenografts in mice effectively, with an increased proportion of memory subsets within circulating CAR T cells of central memory and effector memory subsets. In conclusion, we greatly improved the in vitro and in vivo function of CAR T cells in TGF-β-rich tumor environments by knocking out endogenous TGFBR2 and propose a potentially new method to improve the efficacy of CAR T cell therapy for treating solid tumors.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

3 ta iqtibos0 ta foydalanilgan manba